This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hansen, L. Articles by Pedersen, O. Search for Related Content PubMed PubMed Citation Articles by Hansen, L. Articles by Pedersen, O.

Missense Mutations in the Human Insulin Promoter Factor-1 Gene and Their Relation to Maturity-Onset Diabetes of the Young and Late-Onset Type 2 Diabetes Mellitus in Caucasians¹

Steno Diabetes Center (L.H., S.U., J.N.J., T.H., O.P.) and Hagedorn Research Institute (H.V.P., P.S.), DK-2820 Gentofte, Denmark; Institute of Human Genetics, Panum Institute, University of Copenhagen (H.E.), DK-2200 N Copenhagen, Denmark; and Laboratory of Molecular Pathology of Diabetes, H. San Raffaele Scientific Institute (F.B.), I-20132 Milan, Italy

Address all correspondence and requests for reprints to: Lars Hansen, M.D., Steno Diabetes Center and Hagedorn Research Institute, Niels Steensens Vej 2–6, DK-2820, Gentofte, Denmark.

Abstract

Increasing evidence suggests that defects in genes encoding transcription factors that are expressed in the pancreatic ß-cells may be important contributors to the genetic basis of type 2 diabetes mellitus. Maturity-onset diabetes of the young (MODY) now exists in five subtypes (MODY1–5), four of which are caused by mutations in transcription factors hepatocyte nuclear factor-4 (HNF-4), HNF-1, insulin promoter factor-1 (IPF-1), and HNF-1ß (MODY1, -3, -4, and -5). Recent evidence from the British population even suggested that IPF-1 may be a predisposing gene for type 2 diabetes. Thus, highlighting the potential role of this transcription factor in the genetic basis of Danish and Italian MODY as well as in Danish patients with late-onset type 2 diabetes mellitus, we have examined the human IPF-1 gene for mutations by single strand conformation polymorphism and heteroduplex analysis in 200 Danish patients with late-onset type 2 diabetes and in 44 Danish and Italian MODY patients. In the patients with late-onset type 2 diabetes we identified a noncoding G insertion/deletion polymorphism at nucleotide -108, a silent G54G, and a rare missense D76N variant. Moreover, a Danish MODY patient was carrier of an A140T variant. Neither the D76N nor the A140T segregated with diabetes, and their transcriptional activation of the human insulin promoter expressed in vitro was indistinguishable from that of the wild type (115 ± 21% and 84 ± 12% vs. 100%). We conclude that variants in IPF-1 are not a common cause of MODY or late-onset type 2 diabetes in the Caucasian population, and that in terms of insulin transcription both the N76 and the T140 mutations are likely to represent functionally normal IPF-1 variants with no direct role in the pathogenesis of MODY or late-onset type 2 diabetes mellitus.

This article has been cited by other articles:

				L. W. Harries, J. M. Locke, B. Shields, N. A. Hanley, K. P. Hanley, A. Steele, P. R. Njolstad, S. Ellard, and A. T. Hattersley The Diabetic Phenotype in HNF4A Mutation Carriers Is Moderated By the Expression of HNF4A Isoforms From the P1 Promoter During Fetal Development Diabetes, June 1, 2008; 57(6): 1745 - 1752. [Abstract] [Full Text] [PDF]

				S. C. Elbein, X. Wang, M. A. Karim, B. I. Freedman, D. W. Bowden, A. R. Shuldiner, F. L. Brancati, and W. H. L. Kao Role of a Proline Insertion in the Insulin Promoter Factor 1 (IPF1) Gene in African Americans With Type 2 Diabetes. Diabetes, October 1, 2006; 55(10): 2909 - 2914. [Abstract] [Full Text] [PDF]

				M.-J. Boucher, L. Selander, L. Carlsson, and H. Edlund Phosphorylation Marks IPF1/PDX1 Protein for Degradation by Glycogen Synthase Kinase 3-dependent Mechanisms J. Biol. Chem., March 10, 2006; 281(10): 6395 - 6403. [Abstract] [Full Text] [PDF]

				S. C. Elbein and M. A. Karim Does the Aspartic Acid to Asparagine Substitution at Position 76 in the Pancreas Duodenum Homeobox Gene (PDX1) Cause Late-Onset Type 2 Diabetes? Diabetes Care, August 1, 2004; 27(8): 1968 - 1973. [Abstract] [Full Text] [PDF]

				B. R. Gauthier, T. Brun, E. J. Sarret, H. Ishihara, O. Schaad, P. Descombes, and C. B. Wollheim Oligonucleotide Microarray Analysis Reveals PDX1 as an Essential Regulator of Mitochondrial Metabolism in Rat Islets J. Biol. Chem., July 23, 2004; 279(30): 31121 - 31130. [Abstract] [Full Text] [PDF]

				V. Stanojevic, J. F. Habener, and M. K. Thomas Pancreas Duodenum Homeobox-1 Transcriptional Activation Requires Interactions with p300 Endocrinology, June 1, 2004; 145(6): 2918 - 2928. [Abstract] [Full Text] [PDF]

				F. BERNASSOLA, M. FEDERICI, M. CORAZZARI, A. TERRINONI, M. L. HRIBAL, V. DE LAURENZI, M. RANALLI, O. MASSA, G. SESTI, W.H. IRWIN MCLEAN, et al. Role of transglutaminase 2 in glucose tolerance: knockout mice studies and a putative mutation in a MODY patient FASEB J, September 1, 2002; 16(11): 1371 - 1378. [Abstract] [Full Text] [PDF]

				M. Brissova, M. Shiota, W. E. Nicholson, M. Gannon, S. M. Knobel, D. W. Piston, C. V. E. Wright, and A. C. Powers Reduction in Pancreatic Transcription Factor PDX-1 Impairs Glucose-stimulated Insulin Secretion J. Biol. Chem., March 22, 2002; 277(13): 11225 - 11232. [Abstract] [Full Text] [PDF]

				M. Stumvoll, A. Fritsche, and H.-U. Haring Clinical Characterization of Insulin Secretion as the Basis for Genetic Analyses Diabetes, February 1, 2002; 51(90001): S122 - 129. [Abstract] [Full Text] [PDF]

				R. S. Moisés, A. F. Reis, V. Morel, A. R. Chacra, S. A. Dib, C. Bellanné-Chantelot, and G. Velho Prevalence of Maturity-Onset Diabetes of the Young Mutations in Brazilian Families With Autosomal- Dominant Early-Onset Type 2 Diabetes Diabetes Care, April 1, 2001; 24(4): 786 - 788. [Full Text]